Long-term effect of risankizumab on improved and sustained health-related quality of life over 3 years in patients with moderate to severe Crohn's disease: interim analysis of a phase 2 open-label extension study

(1) University Hospital CHU of Liège,Liège,Belgium

(2) Imelda Hospital,Bonheiden,Belgium

(3) Hospital Clinic de Barcelona,Barcelona,Spain

(4) Robarts Clinical Trials, University of Western Ontario,London,Canada

(5) AbbVie Deutschland GmbH & Co. KG,Ludwigshafen,Germany

(6) AbbVie Inc.,North Chicago,United States

(7) University Hospitals, KU Leuven,Leuven,Belgium

This item was part of the IBD I (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019